News Release: Hemedex Introduces Perfusion Monitoring Products to Costa Rica during COCECATI II Congress 2013

Posted by on Aug 22, 2013 in News Releases

News Release: Hemedex Introduces Perfusion Monitoring Products to Costa Rica during COCECATI II Congress 2013

CAMBRIDGE, Mass. (August 22, 2013) – Hemedex, Inc., a medical-device company, showcased its Bowman Perfusion Monitor® (BPM) and the clinical utility of its use to monitor cerebral blood flow in neurocritical care patients at the recent Congress of the Consortium of Intensive Care Societies of Central America and the Caribbean (COCECATI II) held June 24th- 28th, 2013 in San Jose, Costa Rica.

The annual event hosted neurointensivists, neurologists, neurosurgeons, general practitioners and ICU nurses.

Hemedex exhibited their products, including the Bowman Perfusion Monitor, QFlow 500™ Perfusion Probe and QFlow 500™ Titanium Bolt Kits, in the exhibit hall in conjunction with their new distributor in Costa Rica, Tri D M, S. A. The COCECATI II Congress event marks the introduction and market release of the Hemedex product line in Costa Rica.

Hemedex CEO and President, H. Frederick Bowman, Ph.D. and Vice President of Technology, Scott D. Greenwald, Ph.D., both spoke to the congress attendees regarding the Bowman Perfusion Monitor®, an innovative solution that addresses unmet clinical needs in monitoring absolute levels of cerebral blood flow (CBF) in neurological applications.

“The BPM offers insight for therapy by giving real-time and contextual data alerting clinicians to the onset of swelling-induced ischemia and the onset of vasospasm,” said Bowman. This type of information enables clinicians to react to changes in patient state and to evaluate the effectiveness of interventions in real-time.”

Hemedex would like to give a special thanks to Dr. Jorge Ramirez, President of the Scientific Committee, for organizing the COCECATI II Congress event and extending the invitation to the Hemedex Team to attend, exhibit, and present a plenary lecture.


From left to right: Eduardo Montes de Oca, President, Tri DM, S. A.,  H. Frederick Bowman, Ph.D., CEO and President, Hemedex, Inc., Sergio Montes de Oca, General Manager, Tri DM, S.A., Scott D. Greenwald, Ph.D., Vice President of Technology, Hemedex, Inc.

About TRI DM:

TRI DM, S.A., located in San Jose, Costa Rica, was founded in 1987 and has since been dedicated to enhancing the quality of care via the distribution of state-of-the-art medical equipment. TRI DM, S.A. provides healthcare practitioners the best tools for the management of their patients through their wide range of products and services that benefit patients by providing the best market alternatives in the healthcare areas of anesthesiology, cardiovascular and cardiac surgery, respiratory therapy, neonatology and pediatrics, among others. For more information, visit

About Hemedex, Inc.:

Hemedex, Inc. manufactures patient monitoring technology, the Bowman Perfusion Monitor®, for quantifying tissue blood flow. The Company’s patented technology provides clinicians with a powerful tool, which can provide an early warning of compromised blood flow and help target appropriate therapies rapidly and accurately. Data from the Bowman Perfusion Monitor helps guide physicians in implementing effective treatments quickly, creating the potential to improve patient outcomes and lower costs. Hemedex’s technology addresses unmet needs in many clinical areas such as neurocritical care (e.g., TBI, SAH), neurosurgery (e.g., TAO, EC-IC Bypass, Moya Moya), reconstructive surgery and organ transplantation, among others.  For more information, visit


Communications Team
Hemedex Inc.
617 577 1759 X 46